Search | Page 31 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Transplants With Unlicensed Preserved Cord Blood

    For more details on this clinical trial, including contact information, please see this trial’s ... transplantation if the transplant will occur under an IND research protocol . These units are in current and future inventory at ... to receive NMDP unrelated cord blood units for treatment or research must participate with an locally IRB- approved protocol. Primary ...

    Clinical Trial last updated 04/27/2016 - 3:20pm.

  2. CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

    For more details on this clinical trial, including contact information, please see this trial’s ... Purpose:  This study is a research study involving subjects who are diagnosed with a malignant disease, ...

    Clinical Trial last updated 05/03/2016 - 10:47am.

  3. Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

    For more details on this clinical trial, including contact information, please see this trial’s ... (SCT) between 3 to 15 months after the SCT. In this research study, researchers want to find how well dasatinib can be tolerated, ...

    Clinical Trial last updated 05/03/2016 - 10:43am.

  4. Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

    For more details on this clinical trial, including contact information, please see this trial’s ... HLA-matched unrelated donor (Fred Hutchinson Cancer Research Center [FHCRC] matching allowed will be Grade 1.0 to 2.1) is available ... nodules Liver function abnormalities: Patient with clinical or laboratory evidence of liver disease will be evaluated for the ...

    Clinical Trial last updated 04/28/2016 - 2:45pm.

  5. Prognostic value of telomere attrition in patients with aplastic anemia

    ... measurements are another example of a potentially useful clinical marker to predict outcome in patients with SAA.  Telomeres are ... is ongoing.    In summary, it is an active area of research to utilize TL measurements in the decision making for patients with ...

    Research Review last updated 05/02/2016 - 9:25am.

  6. Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

    For more details on this clinical trial, including contact information, please see this trial’s ... the patient, in the opinion of the PI or LAI, will meet the research phase eligibility criteria and proceed to transplant after induction ... she should inform her treating physician immediately. Research Phase Inclusion Criteria: Verification of donor eligibility ...

    Clinical Trial last updated 04/29/2016 - 1:00pm.

  7. Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

    For more details on this clinical trial, including contact information, please see this trial’s ... Purpose:  This research is being done to learn more about nonmyeloablative bone marrow ...

    Clinical Trial last updated 05/02/2016 - 2:38pm.

  8. Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

    For more details on this clinical trial, including contact information, please see this trial’s ... Purpose:  This research is looking at two conditions, Essential Thrombocythemia (ET) and ...

    Clinical Trial last updated 05/02/2016 - 2:31pm.

  9. Ramon Tiu, MD

    ... in the Department of Translational Hematology and Oncology Research and Department of Hematologic Oncology and Blood Disorders at ... single nucleotide polymorphism arrays, especially in their clinical application in myeloid malignancies like myelodysplastic syndromes ...

    Bio last updated 03/11/2016 - 1:41pm.

  10. Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

    For more details on this clinical trial, including contact information, please see this trial’s ... 1st relapse or > 2nd remission ALL/LL in 1st remission clinical or molecular features indicating a high risk for relapse; or ALL > 2nd ... ) Each patient must be willing to participate as a research subject and must sign an informed consent form. Donor Inclusion ...

    Clinical Trial last updated 04/29/2016 - 1:59pm.